# A Study of Olanzapine After Intranasal and Intramuscular Administration

> **NCT06600477** · PHASE1 · COMPLETED · sponsor: **Neurelis, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** olanzapine

## Key facts

- **NCT ID:** NCT06600477
- **Lead sponsor:** Neurelis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-16
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600477, "A Study of Olanzapine After Intranasal and Intramuscular Administration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06600477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*